GlassScriptPhysician profile
Arun Kachroo
NPI 1609840602
$9,333.09
in general payments reported to CMS, 2019-2025
66 companies · $1,428 in 2025
The $1,428 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $262 · 2021: $1,224 · 2022: $1,561 · 2023: $1,813 · 2024: $1,608 · 2025: $1,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,832 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,832.28 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.29 | 2019-2025 | |
| Biogen, INC. | $935.01 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Ucb, INC. | $677.95 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Lilly USA, LLC | $535.32 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Validus Pharmaceuticals LLC | $533.76 | 2019-2023 | Equetro |
| Pfizer INC. | $527.08 | 2023-2025 | |
| Emd Serono, INC. | $484.59 | 2020-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $470.75 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $386.33 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $266.64 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Scilex Pharmaceuticals INC. | $242.84 | 2023-2025 | Ztlido |
| Biohaven Pharmaceutical Holding Company LTD. | $196.75 | 2022 | |
| Avanir Pharmaceuticals, INC. | $182.27 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $149.62 | 2022-2025 | Purified Cortrophin Gel |
| Adamas Pharmaceuticals, INC. | $139.92 | 2019-2021 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kachroo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.